RecruitingNCT05198154

ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC

A Multicenter, Prospective Clinical Study of Circulating Tumor DNA Analysis to Monitor the Risk of Progression After Long-term Benefit to First-line Immunotherapy in Patients With Advanced NSCLC (CR1STAL)

Sponsor

Fang Wu

Enrollment

100 participants

Start Date

Jan 24, 2022

Study Type

OBSERVATIONAL

Conditions

Advanced Lung Non-Small Cell Carcinoma

Summary

This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a blood test that detects tiny fragments of tumor DNA (called ctDNA) to monitor patients with advanced lung cancer who have responded well to immunotherapy — to catch any signs of cancer coming back earlier than standard scans. **You may be eligible if...** - You are 18 or older - You have advanced non-small cell lung cancer (stage 3B or 4) - Your cancer does not have EGFR, ALK, or ROS1 gene mutations - You have been receiving immunotherapy as your first treatment and have had at least 12 months of response - You are in good physical condition (able to carry out normal activities) **You may NOT be eligible if...** - Your cancer has specific genetic driver mutations (EGFR, ALK, or ROS1 positive) - Your cancer has progressed on immunotherapy - Your overall health is poor Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.